|
 |
European Pharmaceutical Contractor
|
| The European Medicines Agency will start requiring electronic registration submission in the not too distant future; Simon Andriesen at MediLingua BV discusses the implications of translating fragmented pieces of text in XML format
Pharmaceutical and biotech companies, medical device manufacturers and contract research organisations, generally deal with vast amounts of information – many thousands of documents of varying size, ranging from ‘bits and pieces’ to large documents, and sometimes in all 23 languages of the EU, or even more. For larger organisations to survive, it is crucial to professionally manage this information. Content management systems (CMS) have come to play an important role in this respect and the benefits are obvious. Information in such systems is often stored as extensible markup language files (XML files). The product information management (PIM) system, developed by the European Medicines Agency (EMeA), requires registration documents to be submitted electronically, and in XML format. While there are certain advantages of using CMS systems, for writers and perhaps more so for translators, the work has not become easier. In general, medical translators have to deal increasingly with out-of-context fragments of information coming from a CMS, and translators who are involved in the translation of registration documents have to deal with the complexities of PIM.
CONTENT MANAGEMENT – THE GOOD NEWS
Until not too long ago a specific piece of information was usually available as a single electronic file. Even a relatively large document, for example an instruction manual for a medical device, consisted of perhaps a dozen different electronic files – one or two per chapter. With the introduction of document management systems (DMS) and content management systems (CMS), information can be centrally stored and retrieved. Also, the fact that the user of a CMS can store unique pieces of information that may occur several times and in different locations, in a database as individual text blocks and phrases, increases efficiency. |
Read full article >>
|
 |
 |
 |
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
 |

 |
Industry Events |
 |
Small Scale Biomanufacturing – clinical trials, cell & gene therapies
18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol
This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
|